US payers set to battle against high-priced treatments?
1
PharmacoEconomics & Outcomes News 695, p11 - 1 Feb 2014 US payers set to battle against high-priced treatments? New breakthrough drugs with their associated high- price tags are pushing US payers to reconsider covering such treatments, reports Bloomberg’s Drew Armstrong. According to Armstrong, the development of more complex products means that payers face huge costs for new drugs such as Gilead’s new hepatitis C drug sofosbuvir [Sovaldi] which costs $US84 000 for a 12-week course. The Pharmaceutical Researchers and Manufacturers of America (PhRMA) says that payers already make patients try cheaper drugs first so that by the time the patient gets through all the steps they need to get the treatment, they really need it. Last year several payers stopped covering some antidiabetic drugs – as pricing becomes more acute more drugs may be targeted as tough formulary decisions are made. At $84,000 Gilead Hepatitis C Drug Sets Off Payer Revolt. Internet Document : 27 Jan 2014. Available from: URL: http://www.bloomberg.com 803099015 1 PharmacoEconomics & Outcomes News 1 Feb 2014 No. 695 1173-5503/14/0695-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of US payers set to battle against high-priced treatments?
PharmacoEconomics & Outcomes News 695, p11 - 1 Feb 2014
US payers set to battle againsthigh-priced treatments?
New breakthrough drugs with their associated high-price tags are pushing US payers to reconsider coveringsuch treatments, reports Bloomberg’s Drew Armstrong.
According to Armstrong, the development of morecomplex products means that payers face huge costs fornew drugs such as Gilead’s new hepatitis C drugsofosbuvir [Sovaldi] which costs $US84 000 for a12-week course.
The Pharmaceutical Researchers and Manufacturersof America (PhRMA) says that payers already makepatients try cheaper drugs first so that by the time thepatient gets through all the steps they need to get thetreatment, they really need it. Last year several payersstopped covering some antidiabetic drugs – as pricingbecomes more acute more drugs may be targeted astough formulary decisions are made.At $84,000 Gilead Hepatitis C Drug Sets Off Payer Revolt. Internet Document : 27Jan 2014. Available from: URL: http://www.bloomberg.com 803099015
1
PharmacoEconomics & Outcomes News 1 Feb 2014 No. 6951173-5503/14/0695-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
